Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT05780242 Active, not recruiting - COVID-19 Clinical Trials

Recrudescence of Eating Conduct Disorders and Covid-19

TCA-Covid19
Start date: July 12, 2022
Phase:
Study type: Observational

This qualitative study, combining psychiatric and anthropological perspectives, focused on the development and/or worsening of patients' eating disorders since Covid-19, as well as the experiences and perceptions of those around them - such as their family, teachers or staff. School and nursing staff. This multi-site approach will provide a multidimensional perspective on the experience of individuals and those around them, as well as a triangulation of data. The hypotheses to explain the increase in Eating Disorders (EDs) will be addressed through semi-structured interviews offered to study participants.

NCT ID: NCT05779943 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Start date: April 27, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates Fluorine-18 radiohybrid prostate-specific membrane antigen (18F- rhPSMA)-7.3 positron emission tomography (PET)/computed tomography (CT) scans with and without furosemide for the reduction of bladder activity in patients with prostate cancer that has come back (recurrent) based on elevated levels of prostate-specific antigen (PSA) in the blood (biochemical) after prostate surgery (prostatectomy). Furosemide is a diuretic substance that increases the urine flow into the bladder, thereby decreasing the level of radioactivity within the bladder, which may help to see any abnormal areas that could be masked by the radioactivity within the bladder. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, rhPSMA ligand. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. Adding furosemide to 18F-rhPSMA 7.3 PET/CT scans may help to better detect and treat patients with biochemically recurrent prostate cancer.

NCT ID: NCT05736523 Active, not recruiting - Melanoma Clinical Trials

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Start date: September 23, 2020
Phase:
Study type: Observational

This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery Study participants will complete a ctDNA test within 4 weeks of their planned surgical resection of their melanoma. Within 4 weeks post-surgery another ctDNA test will be completed. During these time points stool samples and diet questionnaires will be collected for biospecimen banking.

NCT ID: NCT05673902 Active, not recruiting - Clinical trials for Idiopathic Recurrent Pericarditis

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.

NCT ID: NCT05663125 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas

Start date: December 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to investigate the safety and efficacy of Laser Interstitial Thermal Therapy (LITT) combined with postoperative early use of temozolomide in treating recurrent glioblastomas.

NCT ID: NCT05611645 Active, not recruiting - Glioma Clinical Trials

Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence

Start date: October 1, 2022
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well lose dose bevacizumab with Hypofractionated Stereotactic Radiotherapy (HSRT) works versus bevacizumab alone in treating patients with glioblastoma at first recurrence. The primary endpoint is 6-month progress-free survivaloverall survival after the treatment. Secondary endpoints included overall survival, objective response rate, cognitive function, quality of life and toxicity.

NCT ID: NCT05610293 Active, not recruiting - Surgery Clinical Trials

T1 Squamous Cell Carcinomas of the Lip

Start date: April 1, 2021
Phase:
Study type: Observational

The purpose of this study is to investigate the risk of recurrence and metastasis in patients treated with different surgical margins (5mm vs 10mm) for a T1 squamous cell carcinoma of the lip.

NCT ID: NCT05494788 Active, not recruiting - Clinical trials for Recurrent Pericarditis

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.

NCT ID: NCT05474651 Active, not recruiting - Smoking Cessation Clinical Trials

Influencing Factors and Trigger Mechanism of Relapse in Expectant Fathers Who Quit Smoking

Start date: November 23, 2022
Phase:
Study type: Observational

The purpose of this study is to describe the relapse rate and characteristics of expectant fathers who quit smoking during their wives' pregnancy, to explore the influencing factors and triggering mechanisms,and describe their experience.

NCT ID: NCT05449860 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet Electrodes

Start date: January 28, 2020
Phase: N/A
Study type: Interventional

To investigate the therapeutic effects and treatment results of radiofrequency ablation using combined bipolar and monopolar energy deliver with twin cooled-wet electrodes for recurrent tumor after locoregional treatment in patients with hepatocellular carcinoma.